Alza Corporation

Other

Alza Corporatiton

Patrick S Wong

Felix T Theeuwes

Brian L Barclay

Atul D Ayer

Liang C Dong

Jerry D Childers

George V Guittard

Anthony L Kuczynski

James B Eckenhoff

Jeri D Wright

Hoa T Huynh

Steven D Larsen

Harold M Leeper

Frank Jao

Jimmy B Langston

Michael H Dealey

Virgil A Place

Paul R Magruder

Richard Lewis Cortese

Terry L Burkoth

Vincent Joseph Ferrari

David E Edgren

Lawrence G Hamel

Evangeline Cruz

Eduardo C Sy

Joseph C Deters

Linda E Atkinson

Pamela K Wat

Alejandro C Zaffaroni

Su Il Yum

Eun Soo Lee

Nathan Roth

Francisco Jao

David J Kidney

Steven Espinal

Phyllis I Gardner

Howard B Rosen

Crystal Pollock

Sally I Stephens

Kathy McChesney

Felix A Landrau

David J Enscore

James L Osborne

Brenda J Pollock

Randall G Berggren

Susan M Marks

Fernando E Gumucio

Wouter E Roorda

Pieter Bonsen

Heechung Yang

Glen E Barclay

Vu Anh Nguyen

Juan M Harrison

Robert M Gale

Judy A Magruder

Alan S Michaels

Andrew C Lam

David R Swanson

Bruce B Pharriss

Howard A Carpenter

Scott A Bura

Maureen L Jordan

Ernest S Quan

Si-Hong Yum

Kathy Mc Chesney

Richard L-c Yieh

L G Hamel

Si-Hong A Yum

Richard L-c Yien

Kelly L Smith

Mark DuBois

Joseph C Oeters

Marc L Bartoo

Larry G Hamel

Brian L Barcley

Hoa I Huynh

Myriam T Encarnacion

A method and a system for editing documents online, that in some implementations, simultaneously edits a webpage document, in a webpage file format, and an image document, in an image file format. The webpage document and the image document may have substantially similar visual content. In some implementations, an editing interface is displayed to a client device. The editing interface may have a first portion displaying one or more webpage editing forms for editing the webpage document and a second portion displaying the webpage document or image document being edited. The editing interface accepts editing data from the client device. Both the webpage document and an image document may be updated based on accepted editing data. The image document is updated in part by updating form data retrieved from a database. In some implementations, the updated webpage document is displayed on a webpage and access to the image document is provided from the webpage.

System and a method for web-based editing of documents online with an editing interface and concurrent display to webpages and print documents

A dosage form is disclosed comprising means for delaying the delivery of drug from the dosage form following the administration of the dosage form to a patient in need of drug therapy.

System for delaying drug delivery up to seven hours

The present invention is directed to an oral active agent delivery system and method for delivering discrete units of an active agent formulation to a patient. An active agent formulation chamber containing the active agent formulation and having a fluid passing active agent formulation retainer is placed at a first end into a fluid and at a second end into a patient's mouth. The active agent is delivered when the patient sips on the second end of the chamber.

Oral delivery of discrete units

The invention disclosed pertains to a dosage form comprising an agent formulation comprising drug and pharmaceutical carrier of cooperating particle size and means for dispensing the agent formulation from the dosage form.

Dosage form, process of making and using same

A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy.

Therapy for neurological diseases

The present invention is directed to an active agent dosage form that is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has an insoluble material circumscribing a portion of the surface of the matrix. The invention is also directed to a method of making the active agent dosage form.

Banded prolonged release active agent dosage form

The present invention is directed to a pharmaceutical formulation of a therapeutic polypeptide together with a permeation-enhancing mixture of sodium salicylate and an oil to provide enhanced absorption of the polypeptide through the wall of the gastrointestinal tract, and particularly of the colon, after oral administration, the amount of oil being from about 10 wt % to about 30 wt %, preferably from about 15 wt % to about 25 wt %, of the total formulation and the amount of sodium salicylate being from about 70 wt % to about 90 wt %, preferably from about 75 wt % to about 85 wt %, of the total formulation. The polypeptide may be non-lyophilized. The pharmaceutical formulation is characterized as a solid, which provides a convenient and improved format for handling and storage and for the preparation of oral dosage forms (such as pills, capsules and delivery vessels) containing a homogeneous mixture of ingredients.

Peptide formulation

The present invention is directed to an oral active agent delivery system and method for delivering discrete units of an active agent formulation to a patient. An active agent formulation chamber containing the active agent formulation and having a fluid passing active agent formulation retainer is placed at one end into a fluid and at a second end into a patient's mouth. The active agent is delivered when the patient sips on the end of the chamber.

This invention pertains to a dosage form for the management of epilepsies wherein the dosage form comprises administering valproic acid or a valproic acid derivative at a continuous rate over an extended time.

Sustained antiepileptic therapy

A dosage form is disclosed for delivering an antiepileptic drug, which dosage form comprises a laminated wall for maintaining the integrity of the dosage form and of the antiepileptic drug.

Dosage form comprising antiepileptic drug

A dispenser for use in a fluid environment of use which is capable of the delivery of one or a plurality of discrete active agent-containing units in any desired delivery pattern or profile. It also can provide for the initially delayed delivery of an active agent to the environment of use and for high accuracy in the timing of delivery of the active agent.

Osmotic device for delayed delivery of agent

A dosage form is disclosed for delivering an antiepileptic drug, which dosage form comprises for maintaining the integrity of the dosage form and of the antiepileptic drug.

Method for treating epilepsies

The present invention is directed to a fluid-imbibing drug delivery device which is useful for the initial delayed delivery of an active agent formulation to a fluid environment of use, the initial delay period to startup or activation of the device being of a predetermined length of time. The delivery of the agent formulation from the dispensing device is continued until essentially all of the active agent formulation is delivered as a result of the fluid inhibition into a fluid flow path in the housing of the device and the expansion of an expansion agent in the active agent delivery chamber.

Drug delivery device with minimal residual drug retention

A dosage form is disclosed comprising means for lessening the tackiness and/or irritation of the components of the dosage form to mucosal tissue. The dosage form provides means for forming in the dosage form a floc comprising a drug, which floc, when delivered from the dosage form, lessens the tackiness and/or irritation of the mucosal tissue of a warm-blooded recipient.

Method for administering steroid

Effective therapy for epilepsies

Growing community of inventors

Palo Alto, CA, United States of America

Patrick S Wong